Treatment of impetigo and antimicrobial resistance

  16 October 2021

A recent review in Journal of Drugs in Dermatology reviewed the information provided to physicians and stakeholders regarding antimicrobial resistance (AMR) in the treatment of impetigo.

Impetigo is a contagious bacterial infection that affects the superficial layers of the skin, and topical agents prescribed for the condition are seeing an increase in AMR worldwide, causing treatment to fail. In response, the World Health Organization (WHO) developed a comprehensive action plan on AMR but omitted information on the AMR management program for topical antibiotics.

Further reading: Remo News
Author(s): Remo News
Effective Surveillance  


Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition

Technology Database

Display your AMR Technology, Product and Service

Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.

Read more and make your own Technology Page >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!